4.1 Article

Changing Practice Patterns of Deep Brain Stimulation in Parkinson's Disease and Essential Tremor in the USA

期刊

STEREOTACTIC AND FUNCTIONAL NEUROSURGERY
卷 90, 期 1, 页码 25-29

出版社

KARGER
DOI: 10.1159/000333834

关键词

Neurosurgery; Socioeconomics; Deep brain stimulation; Essential tremor

资金

  1. Howard Hughes Medical Institute

向作者/读者索取更多资源

Background: Randomized controlled studies have shown deep brain stimulation (DBS) to be an effective treatment for Parkinson's disease (PD). Outside of large-center studies, little is known about trends in DBS use in the USA. Objectives: We employ the Nationwide Inpatient Sample to look at changes in DBS utilization over time. Methods: We identified all individuals with PD (332.0) and essential tremor (ET) (333.1) who underwent DBS (02.93) from 1998 to 2007. We examined demographics, hospital status, comorbidities, and in-hospital systemic/technical complications. DBS patients from 2000 and 2007 were compared using chi(2) tests. Results: PD patients from the 2007 sample who underwent DBS were older (p = 0.01). Both ET and PD patients had significantly more comorbidities in 2007 (p <0.001). In-hospital complications decreased from 3.8 to 2.8%. DBS was performed in medium- or high-volume centers in 70% of cases in 2000 and in 50% in 2007. In all groups, a majority of cases (range 65-71%) underwent DBS at hospitals in the western and southern USA. Conclusions: Patients who underwent DBS in the 2007 sample were older and had more comorbidities than those in the 2000 sample; in-hospital complications remained low. Understanding trends in DBS is helpful in assessing how the technology is adopted and what relationships should be further explored. Copyright (C) 2011 S. Karger AG, Basel

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.1
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

Fluoropyrimidine-Associated Cardiotoxicity: A Retrospective Case-Control Study

Inbar Raber, Sarah Warack, Jaya Kanduri, Abby Pribish, Anuradha Godishala, Arielle Abovich, Anna Orbite, Sujithraj Dommaraju, Morgan Frazer, Mary Linton Peters, Aarti Asnani

ONCOLOGIST (2020)

Letter Oncology

Untitled Reply

Inbar Raber, Mary Linton Peters, Aarti Asnani

ONCOLOGIST (2020)

Meeting Abstract Oncology

A phase I study of LY3410738, a first-in-class covalent inhibitor of mutant IDH1 in cholangiocarcinoma and other advanced solid tumors.

James Michael Pauff, Kyriakos P. Papadopoulos, Filip Janku, Anita Ahmed Turk, Lipika Goyal, Rachna T. Shroff, Toshio Shimizu, Masafumi Ikeda, Nilofer Saba Azad, James M. Cleary, Mary Linton Bounetheau Peters, Mitesh J. Borad, Kurt A. Jaeckle, Sani Haider Kizilbash, Rebecca Tupper, Carrie E. Furin, Matthew P. Hanley, Elizabeth Goodwin Hill, Xu Xiaojian, James J. Harding

JOURNAL OF CLINICAL ONCOLOGY (2021)

Article Oncology

Time to SARS-CoV-2 clearance among patients with cancer and COVID-19

Wenxin Xu, Andrew J. Piper-Vallillo, Poorva Bindal, Jonathan Wischhusen, Jaymin M. Patel, Daniel B. Costa, Mary Linton B. Peters

Summary: The clearance times of SARS-CoV-2 in cancer patients vary significantly depending on the criteria used, potentially leading to delays in cancer care and increased use of clearance testing.

CANCER MEDICINE (2021)

Meeting Abstract Oncology

A phase Ib study of NUC-3373, a targeted inhibitor of thymidylate synthase, in combination with standard therapies in patients with advanced colorectal cancer (NuTide:302)

J. Berlin, A. L. Coveler, K. K. Ciombor, F. Kazmi, J. Graham, M. L. Peters, J. W. Clark, M. Myers, A. De Gramont, T. R. J. Evans, S. Blagden

ANNALS OF ONCOLOGY (2021)

Editorial Material Medicine, General & Internal

K Awards: The Journey of a Thousand Steps

Stephanie L. Santoro, Mary Linton B. Peters

ANNALS OF INTERNAL MEDICINE (2021)

Article Oncology

Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer

Joseph E. Grossman, Lakshmi Muthuswamy, Ling Huang, Dipikaa Akshinthala, Sofia Perea, Raul S. Gonzalez, Leo L. Tsai, Jonah Cohen, Bruno Bockorny, Andrea J. Bullock, Benjamin Schlechter, Mary Linton B. Peters, Catherine Conahan, Supraja Narasimhan, Christine Lim, Roger B. Davis, Robert Besaw, Mandeep S. Sawhney, Douglas Pleskow, Tyler M. Berzin, Martin Smith, Tara S. Kent, Mark Callery, Senthil K. Muthuswamy, Manuel Hidalgo

Summary: This pilot feasibility trial investigated the use of patient-derived organoids (PDOs) to guide personalized therapy for pancreatic ductal adenocarcinoma (PDAC). The study found that the drug sensitivity of PDOs can predict the clinical outcome of patients and is correlated with treatment responses.

CLINICAL CANCER RESEARCH (2022)

Article Gastroenterology & Hepatology

Duration and cost-effectiveness of hepatocellular carcinoma surveillance in hepatitis C patients after viral eradication

Peter P. Mueller, Qiushi Chen, Turgay Ayer, Gizem S. Nemutlu, Ali Hajjar, Emily D. Bethea, Mary Linton B. Peters, Brian P. Lee, Naveed Z. Janjua, Fasiha Kanwal, Jagpreet Chhatwal

Summary: This study evaluated the cost-effectiveness of biannual surveillance for hepatocellular carcinoma (HCC) in patients cured of hepatitis C. The findings suggest that biannual surveillance is cost-effective until the age of 70 for patients with cirrhosis, and until the age of 60 for patients with stable advanced fibrosis.

JOURNAL OF HEPATOLOGY (2022)

Article Gastroenterology & Hepatology

Genetic testing to guide screening for pancreatic ductal adenocarcinoma: Results of a microsimulation model

Mary Linton B. Peters, Andrew Eckel, Anna Lietz, Claudia Seguin, Peter Mueller, Chin Hur, Pari Pandharipande

Summary: Genetic testing of first-degree relatives can inform targeted screening for pancreatic ductal adenocarcinoma, leading to potential gains in life expectancy.

PANCREATOLOGY (2022)

Article Medicine, General & Internal

Partial response in non-resectable adenosquamous carcinoma of the pancreas with high tumour mutation burden treated with gemcitabine, nab-paclitaxel and pembrolizumab

Rodrigo Paredes de la Fuente, James W. Doolin, Mary Linton Peters

Summary: A previously healthy man in his 60s was diagnosed with a rare histological subtype of pancreatic cancer, adenosquamous carcinoma. Somatic mutation profiling revealed microsatellite instability and high tumor mutational burden. Combination therapy with gemcitabine, nab-paclitaxel, and pembrolizumab resulted in a sustained response, highlighting the importance of somatic testing for tailored therapy in pancreatic cancer.

BMJ CASE REPORTS (2023)

Article Oncology

Updated COVID-19 clearance time among patients with cancer in the Delta and Omicron waves

Zachary M. Avigan, Rodrigo Paredes, Leora S. Boussi, Barbara D. Lam, Meghan E. Shea, Matthew J. Weinstock, Mary Linton B. Peters

Summary: COVID-19 clearance remains prolonged in oncology patients. Single-negative test clearance can reduce delays in care, but has a higher risk of recurrence. Clearance by a predefined waiting period is required to achieve a higher negative rate.

CANCER MEDICINE (2023)

Meeting Abstract Oncology

Association of immune related adverse events with superior outcomes in patients with hepatocellular carcinoma (HCC) treated with nivolumab.

Lorena Ostios-Garcia, David Ramiro-Cortijo, Mary Linton Bounetheau Peters, Andrea J. Bullock

JOURNAL OF CLINICAL ONCOLOGY (2020)

Meeting Abstract Oncology

Time to COVID-19 RT-PCR clearance among patients with cancer.

Wenxin Xu, Andrew Piper-Vallillo, Poorva Bindal, Jonathan W. Wischhusen, Jaymin M. Patel, Daniel Botelho Costa, Mary Linton Bounetheau Peters

JOURNAL OF CLINICAL ONCOLOGY (2020)

Meeting Abstract Oncology

GI oncology molecular tumor board: Fostering collaboration and clinical education for personalized therapy.

Joseph Elan Grossman, Andrea J. Bullock, Susana Angarita, Bruno Bockorny, Farshid Dayyani, Molly Hurley, Kimberly McGregor, Eirini Pectasides, Mary Linton Bounetheau Peters, Venkataprasanth P. Reddy, Benjamin L. Schlechter, Mehrad Tavallai, Jessica A. Zerillo

JOURNAL OF CLINICAL ONCOLOGY (2020)

Meeting Abstract Oncology

Comparison of the clinical features, treatment patterns, and tumor mutations of patients with intrahepatic (ICC) and extrahepatic (ECC) cholangiocarcinoma

Leon Pappas, Stephanie Reyes, Aishwarya Lanka, Rachna T. Shroff, Tri Minh Le, Osama E. Rahma, Andrea Grace Bocobo, Mitesh J. Borad, Thomas DeLeon, Kabir Mody, Marc Thomas Roth, Mary Linton Bounetheau Peters, Laura Williams Goff, Kylie Boyhen, Christine VanCott, Nora Horick, Andrew X. Zhu, Milind M. Javle, Robin Kate Kelley, Lipika Goyal

JOURNAL OF CLINICAL ONCOLOGY (2020)

暂无数据